

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
1	17/SC/0142	215503	The 65 Trial (v1.0)	20/03/2017	07/07/2017	24/04/2017	11/07/2017	17/07/2017	31/07/2017	08/09/2017	Benchmark Met
2	17/SC/0039	220282	MAGPIE	03/05/2017	05/07/2017	18/04/2017	07/07/2017	11/07/2017	07/08/2017	14/08/2017	Benchmark Met
3	16/LO/2141	200571	Biomed	06/06/2017	07/07/2017	06/04/2017	07/07/2017	07/07/2017	12/07/2017	27/07/2017	Benchmark Met
4	16/NW/0629	211995	CF START	15/08/2017	08/09/2017	22/09/2016	05/10/2017	05/10/2017	14/12/2017	09/01/2018	Sponsor
5	17/NW/0223	219119	Evaluation of PKU explore	08/08/2017	07/09/2017	22/04/2017	14/09/2017	14/09/2017	29/09/2017	24/10/2017	Benchmark Met
6	17/EM/0152	216307	Post-transplant Gilteritinib maintenance in acute myeloid leukaemia	19/10/2016	15/09/2017	21/07/2017	06/12/2017	15/12/2017	08/01/2018	17/01/2018	Sponsor
7	17/LO/0038	182633	UK P3BEP Trial	22/05/2017	22/09/2017	06/04/2017	05/10/2017	13/10/2017	18/10/2017		Neither
8	16/WS/0089	197457	PARADIGM-2	09/06/2017	27/07/2017	16/12/2016	02/08/2017	15/08/2017	31/08/2017	11/09/2017	Benchmark Met
9	17/LO/0023	215490	MUK nine b: OPTIMUM	12/01/2017	30/08/2017	30/03/2017	12/01/2018	12/01/2018	17/01/2018		Both
10	17/LO/0249	220398	CO39385: Study of Atezolizumab + Enzalutamide vs Enzalutamide in mCRPC	16/06/2017	13/07/2017	28/04/2017	10/08/2017	22/08/2017	16/11/2017		Sponsor
11	17/SC/0228	219158	Javelin Head and Neck	16/12/2016	02/08/2017	24/07/2017	24/11/2017	05/12/2017	17/01/2018	23/03/2018	Both
12	16/WS/0165	190574	ADSCaN.	19/07/2017	02/08/2017	13/02/2017	31/08/2017	28/09/2017	22/12/2017	22/03/2018	Both
13	17/WA/0087	222840	The Caravaggio Study	26/06/2017	14/09/2017	06/07/2017	06/10/2017	10/10/2017	12/10/2017	10/11/2017	Benchmark Met
14	17/LO/1174	229691	Phase 2 of Filgotinib in patients with active non-infectious uveitis	19/06/2017	27/09/2017	22/08/2017	28/10/2017	30/11/2017	04/12/2017		Neither
15	17/WM/0110	212527	PHITT	28/06/2017	12/10/2017	28/04/2017	29/11/2017	29/11/2017	29/11/2017	30/11/2017	Benchmark Met
16	16/SC/0271	187103	plasmaMATCH	16/06/2017	16/10/2017	21/09/2016	10/11/2017	15/11/2017	24/11/2017	27/11/2017	Benchmark Met
17	16/LO/0680	186642	SMILE (PENTA 17)	10/11/2016	09/11/2017	28/07/2016	21/12/2017	05/01/2018	06/03/2018		Neither
18	17/LO/1656	229212	IMspire 170	18/08/2017	09/11/2017	14/11/2017	22/11/2017	05/12/2017	11/12/2017	12/01/2018	Benchmark Met
19	17/LO/1865	232414	Combination therapy with isatuximab in patients with multiple myeloma	11/04/2017	21/02/2018	13/12/2017	21/03/2018	03/04/2018	20/04/2018	21/06/2018	Neither
20	17/SW/0174	228278	A Phase 2 Clinical Trial in Patients with AML version amend 4	11/09/2017	26/02/2018	20/02/2018	19/01/2018	19/03/2018	06/04/2018		Neither
21	16/NS/0106	212541	RAACENO	11/10/2017	11/10/2017	04/04/2017	19/10/2017	24/11/2017	13/12/2017	21/02/2018	Neither
22	17/LO/0334	214459	FLO-ELA	16/11/2017	24/11/2017	29/03/2017	09/01/2018	08/02/2018	05/03/2018	15/03/2018	Sponsor
23	17/EM/0301	209448	The SANDWICH Trial	04/08/2017	05/12/2017	29/09/2017	14/12/2017	14/12/2017	05/02/2018	06/02/2018	Benchmark Met
24	15/WA/0391	180498	MONOCLE	23/01/2017	04/07/2017	16/11/2016	06/07/2017	07/07/2017	07/07/2017	11/07/2017	Benchmark Met
25	17/YH/0392	230501	BI 1467335 in patients with diabetic retinopathy.	04/08/2017	13/12/2017	26/01/2017	15/01/2018	23/01/2018	19/02/2018		Sponsor
26	17/LO/1943	233068	Phase III study of inclisiran sodium in subjects with HeFH	09/10/2017	02/01/2018	10/01/2018	24/01/2018	25/01/2018			Sponsor
27	17/EE/0474	229785	AdAPT: Adenovirus after Allogeneic Paediatric Transplantation	24/11/2017	26/01/2018	05/01/2018	19/04/2018	20/04/2018	02/05/2018		Both
28	16/LO/1502	178292	CTC-STOP	25/01/2018	23/04/2018	07/10/2016	05/06/2018	05/06/2018			70 days not yet reached
29	16/ES/0110	207747	TOPaZ study	13/01/2017	15/05/2018	12/01/2017	15/05/2018	16/05/2018			70 days not yet reached
30	18/SW/0002	233850	CONSTANT	12/10/2017	20/02/2018	20/02/2018	22/02/2018	22/02/2018	05/03/2018	21/03/2018	Benchmark Met

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
31	17/SS/0082	222441	SoSTART	08/02/2018	27/02/2018	05/10/2017	27/02/2018	04/04/2018	11/04/2018		Neither
32	17/EE/0437	233853	AQUILA (54767414SMM3001)	09/08/2017	28/02/2018	10/01/2018	13/04/2018	11/05/2018	11/05/2018	22/05/2018	Neither
33	16/LO/1495	207629	SPACE	05/12/2017	09/03/2018	12/06/2017	09/03/2018	12/03/2018	17/04/2018		Both
34	17/SC/0345	225047	A Single-dose Pharmacokinetics Study of MK-7655A in Pediatric Subjects	14/07/2017	15/03/2018	05/10/2017	23/05/2018	29/05/2018	21/06/2018		Both
35	16/EE/0446	214004	Niraparib in men with mCRPC and DNA repair anomalies	05/02/2018	16/03/2018	04/01/2017	13/03/2018	16/03/2018	03/05/2018		Sponsor
36	17/SW/0201	180937	MiBRVO	01/01/2015	08/05/2018	06/04/2018	08/05/2018	11/05/2018	30/05/2018		70 days not yet reached
37	17/SW/0202	180940	MiCRVO	01/01/2015	08/05/2018	29/01/2018	08/05/2018	11/05/2018	30/05/2018		70 days not yet reached
38	17/SC/0471	180934	Oral Minocycline for GA	01/01/2015	23/03/2018	13/03/2018	23/04/2018	30/04/2018	02/05/2018	11/05/2018	Benchmark Met
39	18/SC/0055	239091	Be on the TEAM: Teenagers Against Meningitis	18/12/2017	26/03/2018	05/03/2018	28/03/2018	29/03/2018	11/04/2018	13/04/2018	Benchmark Met
40	17/SW/0273	235783	SB11-G31-AMD-Comparison of efficacy&safety of SB11 and Lucentis in AMD	21/07/2017	26/03/2018	22/01/2018	15/03/2018	28/03/2018	23/04/2018	02/05/2018	Benchmark Met
41	18/SC/0015	236685	Adjuvant canakinumab vs placebo in stages IB, II- IIIA resected NSCLC	16/02/2018	27/03/2018	23/02/2018	11/04/2018	13/04/2018	27/04/2018	07/06/2018	Neither
42	16/LO/1979	193891	STATEC	19/07/2016	09/01/2018	20/12/2016	16/01/2018	18/01/2018	23/02/2018	07/03/2018	Benchmark Met
43	17/EE/0040	222216	ENCIRCLE Emergency Cerclage in Twins at Imminent Risk of preterm birth	12/01/2018	16/01/2018	02/03/2017	21/02/2018	22/02/2018	26/03/2018		Neither
44	17/LO/0108	221119	MASTER DAPT	01/02/2018	13/02/2018	10/04/2017	27/02/2018	05/04/2018	16/04/2018	16/04/2018	Benchmark Met
45	18/LO/0205	211278	Thermic-3	28/02/2018	16/03/2018	16/03/2018	16/03/2018	04/05/2018	04/05/2018	20/06/2018	Sponsor
46	16/LO/2186	188540	IMAT-Neuroblastoma	27/10/2017	03/05/2018	17/01/2017	03/05/2018	03/05/2018	04/05/2018	14/05/2018	Benchmark Met
47	17/LO/0731	219463	PIVOTALboost	12/09/2017	21/03/2018	27/07/2017	16/04/2018	23/04/2018	13/06/2018		Sponsor
48	17/NW/0529	226070	PPAC2: Packing of Perianal Abscess Cavities 2	01/03/2018	27/03/2018	05/12/2017	05/04/2018	08/05/2018	04/06/2018	20/06/2018	Sponsor
49	17/NW/0333	223199	Faecal volatiles in children with inflammatory bowel disease	14/09/2017	15/09/2017	18/07/2017	10/11/2017	10/11/2017	14/11/2017	21/11/2017	Benchmark Met
50	17/LO/1472	229826	LN-145 in Advanced Cervical Carcinoma	13/11/2017	19/02/2018	27/10/2017	20/05/2018	31/05/2018	07/06/2018	13/06/2018	NHS Provider
51	17/EM/0468	234972	A3921104 - Tofacitinib for treatment of Juvenile Idiopathic Arthritis	13/09/2017	04/04/2018	27/03/2018	05/04/2018	10/04/2018	26/04/2018		Neither
52	17/YH/0381	225986	GAP Study: Gabapentin in Post Surgery Pain	17/01/2018	04/04/2018	09/01/2018	05/04/2018	05/04/2018	12/04/2018	24/04/2018	Benchmark Met
53	17/LO/0933	220629	Sapphire Study	01/06/2017	09/04/2018		23/03/2018	11/04/2018			Sponsor
54	16/SC/0526	208162	EYS606-CT1	07/09/2016	10/04/2018	05/06/2017	24/04/2018	09/05/2018	10/05/2018	06/06/2018	Benchmark Met
55	17/LO/1055	228923	Elective rituximab in TTP	11/12/2017	11/04/2018	31/07/2017	11/04/2018	08/05/2018			Neither
56	17/EM/0355	229043	SPIRIT 2	18/08/2017	12/04/2018	10/11/2017	30/04/2018	03/05/2018	15/06/2018		Sponsor
57	17/NE/0151	223815	SGI-110 vs Treatment Choice in Adults with Previously Treated AML	24/08/2017	13/04/2018	19/07/2017	19/04/2018	20/04/2018	23/04/2018	23/04/2018	Benchmark Met

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
58	18/LO/0683	239811	YO40245 (IMBrave150) - Atezolizumab & Bevacizumab Vs. Sorafenib in HCC	22/01/2018	16/04/2018	13/06/2018					Neither
59	18/EM/0015	235158	A3921145: A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)	16/10/2017	17/04/2018	03/04/2018					Sponsor
60	16/EE/0324	203951	Prophylactic and Pre-emptive DLI for myeloid malignancies (PRO-DLI)	10/11/2017	30/04/2018	08/09/2016	30/04/2018	30/04/2018	30/04/2018	15/05/2018	Benchmark Met
61	17/EE/0368	213669	Study into the Reversal of Septic Shock with Landiolol (Beta Blockade)	16/04/2018	02/05/2018	10/11/2017	15/06/2018	21/06/2018			70 days not yet reached
62	18/LO/0126	239586	Blinded, preliminary feasibility study for Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE 210201 Administered Intravenously to Patients with Duchenne Muscular Dystrophy	14/12/2017	02/05/2018	12/04/2018					70 days not yet reached
63	18/EM/0027	235145	OPT-302 with ranibizumab for the treatment of wet AMD	15/09/2017	04/05/2018	28/02/2018	07/06/2018	07/06/2018	20/06/2018		70 days not yet reached
64	17/LO/1711	234276	Synbiotic Extensively Hydrolysed Feed Study	14/02/2018	10/05/2018	24/10/2017	18/05/2018	22/05/2018			70 days not yet reached
65	17/WS/0142	221370	PRIMUS 001	12/01/2018	21/05/2018	07/09/2017					70 days not yet reached
66	18/NW/0100	235042	BATCH Trial	09/03/2018	23/05/2018	13/04/2018	27/06/2018	29/06/2018			70 days not yet reached
67	17/LO/2135	223997	Best of Radiotherapy vs Best of Surgery	03/04/2018	04/06/2018	12/03/2018					70 days not yet reached
68	17/WS/0147	184216	PrecisionPanc	06/02/2018	08/06/2018	05/01/2018					70 days not yet reached
69	17/SW/0221	232448	(CAIN457K2340) Secukinumab compared with GP2017 in Active AS	30/01/2018	20/06/2018	28/11/2017					70 days not yet reached
70	18/EE/0176	236637	DELPHINUS: Daratumumab in paediatric and young adults with ALL/LL	20/02/2018	21/06/2018						70 days not yet reached
71	18/LO/0439	240940	A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma - CA224047	14/03/2018	26/06/2018	26/06/2018	20/06/2018	27/06/2018	27/06/2018		70 days not yet reached
72	18/LO/0378	234232	PIONEER III	03/04/2017	28/06/2018	22/06/2018	09/12/2017				70 days not yet reached